Akebia Therapeutics, Inc. logo AKBA - Akebia Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 7
HOLD 3
SELL 1
STRONG
SELL 0
| PRICE TARGET: $4.00 DETAILS
HIGH: $4.00
LOW: $4.00
MEDIAN: $4.00
CONSENSUS: $4.00
UPSIDE: 185.71%

Stock News

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to purchase an aggregate of 125,600 shares of Akebia's common stock on June 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Jul 02, 2026 12:05 PM • globenewswire.com
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO 2 VATE clinical trial program Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's largest privately held and fastest-growing kidney care provider, are pleased to announce today the decision by USRC Kidney Research to stop the Vafseo Outcomes In Center Experience (VOICE) trial following a planned interim analysis.

Jun 30, 2026 04:00 AM • globenewswire.com
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it has been notified of eligibility to extend the expiration of a composition of matter patent covering Vafseo® (vadadustat).

Jun 10, 2026 04:00 AM • globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Jun 01, 2026 12:05 PM • globenewswire.com
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.

May 28, 2026 04:00 AM • globenewswire.com
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Q1 2026 Vafseo® (vadadustat) net product revenues grew to  $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST CAMBRIDGE, Mass.

May 07, 2026 03:00 AM • globenewswire.com
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the Journal of the American Society of Nephrology (JASN), a leading, high-impact, peer-reviewed journal in nephrology.

May 04, 2026 04:00 AM • globenewswire.com
Ionis Pharmaceuticals (NASDAQ:IONS) and Akebia Therapeutics (NASDAQ:AKBA) Financial Analysis

Ionis Pharmaceuticals (NASDAQ:IONS) and Akebia Therapeutics (NASDAQ:AKBA) Financial Analysis

Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends. Volatility and Risk Ionis Pharmaceuticals has a beta

Apr 18, 2026 12:11 AM • defenseworld.net
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI).

Apr 13, 2026 04:00 AM • globenewswire.com
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets

Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets

Akebia Therapeutics (NASDAQ: AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial anemia franchise while advancing three kidney disease pipeline programs: praliciguat in focal segmental glomerulosclerosis (FSGS), the tissue-targeted complement inhibitor AKB-097 (abribafisp) in complement-mediated kidney diseases, and AKB-9090 in cardiac surgery-associated acute kidney injury (CSA-AKI). Commercial backdrop: Vafseo growth

Apr 03, 2026 09:05 PM • defenseworld.net

Price Targets